MediaAlpha Jumps 20% on Q3 Beat, Analysts Chase the Move

MAX heads into its November 2 earnings date having already reported Q3 results, with the stock up 20% on the day of the announcement and analysts lifting targets across the board to catch up with the move.

The rally is sharp and broad-based. Over the past month the stock has gained 54%, closing at $14.13. That price action outpaces every correlated peer by a wide margin: QNST rose just 2% on the day and is slightly lower on the week, while EVER is barely flat and YELP has fallen more than 6% on the week. The options market has not turned defensive despite the run: the put/call ratio of 0.139 sits marginally below its 20-day average of 0.141, a level that is close to the 52-week low of 0.007 in structure rather than the 52-week high of 0.448. Call demand has dominated the book, consistent with a market still positioned for further upside rather than bracing for a pullback. Short interest, at 5.6% of free float, rose roughly 19% over the past week as some traders moved to fade the move. Even so, borrowing conditions remain very loose: availability runs at 1,339%, meaning there are more than thirteen shares available in the lending pool for every one currently borrowed, and the cost to borrow has more than halved over the past month to just 0.51%.

The analyst community is chasing the stock higher but with divided conviction. Within the past 24 hours, Goldman Sachs raised its target to $13 while holding a Neutral rating, JP Morgan followed to $16 also on a Neutral, and RBC Capital lifted to $17 with an Outperform. Canaccord Genuity was the most aggressive, raising to $18 and keeping a Buy. The mean consensus target of $15.43 now sits modestly above the current price, but Goldman's $13 target is already below where the stock trades, a notable drag on the bull narrative from a bellwether firm. The bull case rests on P&C vertical momentum: Q3 transaction value reached $589 million, up 30% year-over-year, with the P&C segment surging 42%, driven by improved carrier profitability feeding back into customer acquisition spending. Bears point to the Q4 guide of $280 to $300 million, which represents a decline of roughly 3.5% year-over-year at the midpoint and trails the market's prior expectation of around $308 million, alongside a 40% collapse in Health TV revenue that raises questions about the breadth of the recovery.

The ownership register carries an important structural note. Two Schedule 13D filers are on record at ORTEX: White Mountains Insurance Group holds 33% of the class and filed a 13D/A amendment in May 2026 after increasing its stake; director Eugene Nonko holds roughly 9.8% on a 13D/A filed in August 2026, though his most recent SEC Form 4 filings show he has been selling steadily under a 10b5-1 plan at prices around $11.60 to $11.92, well below where the stock now trades. That plan-driven selling, executed before the Q3 bounce, reduces its informational signal but it does mean the largest individual insider has been trimming into strength. Stakes are as last disclosed around the 5% threshold; holders dropping below that level may not file again. Divisadero Street Capital, a new 13G filer in July 2026, also holds 5.9%.

The November 2 print is less about confirming Q3 (already released) and more about whether management's Q4 guidance range proves conservative or whether the Health TV drag and the broader deceleration signal structural limits to how far the P&C recovery alone can carry growth.